The Pharma Data

APRIL 16, 2021

–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) (injection for intravenous use), in combination with fluoropyrimidine- and platinum-containing chemotherapy, was approved by the U.S. to 0.90; P =0.0002), as well as in patients with PD-L1 combined positive score (CPS) ?

HR 52

HR Dermatology Trials Clinical Trials 52

The Pharma Data

AUGUST 22, 2021

1 This application was approved under the FDA’s Real-Time Oncology Review (RTOR) pilot program, which aims to ensure that safe and effective treatments are available to patients as early as possible. to 0.86; P =0.0008). to 0.77; P =0.0005). Cardiovascular, Immunology and Oncology, Bristol Myers Squibb. “UC

Drugs 52

Drugs HR FDA Approval Trials 52

The Pharma Data

JANUARY 13, 2021

We are humbled by the expeditious review of our supplemental new drug application and hope our broad development program for tislelizumab will continue its momentum and benefit additional patients,” said Wendy Yan, Senior Vice President and Global Head of Regulatory Affairs at BeiGene. ii She J, Yang P, Hong Q, et al.

Production 52

Production Trials Antibody Clinical Trials 52

The Pharma Data

APRIL 16, 2021

–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo ® (nivolumab) in combination with Cabometyx ® (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma (RCC). PRINCETON, N.J.–(BUSINESS months vs. 8.3

HR 52

HR Trials Medicine Clinical Trials 52

The Pharma Data

DECEMBER 27, 2020

A marketing authorization application (MAA) for BRUKINSA for the treatment of patients with WM who have received at least one prior therapy or as first-line treatment for patients unsuitable for chemo-immunotherapy has been accepted by the European Medicines Agency (EMA). i Moreau P, Richardson PG, Cavo M, et al. Carfilzomib.

Production 52

Production Drugs Clinical Trials Clinical Trials 52